How much did the people who believed in you matter to your success? 🌟🤝 For #TeamSanofi athlete Amandine Buchard and Arnaud DOURLENS, our first torchbearer for the Olympic Torch Relay Paris 2024, their supporters make sure they never settle. #IgnitingPotential #WeNeverSettle #Paris2024 Paris 2024 - Comité d'organisation des Jeux Olympiques et Paralympiques de 2024
Sanofi
Fabrication de produits pharmaceutiques
Paris, France 4 042 574 abonnés
À propos
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
- Site web
-
http://www.sanofi.com
Lien externe pour Sanofi
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Paris, France
- Type
- Société cotée en bourse
- Domaines
- vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases et consumer healthcare
Lieux
Employés chez Sanofi
Nouvelles
-
Ready for the Olympic and Paralympic Games #Paris2024? We can't wait to welcome athletes, sports fans, and Sanofians from around the world at our very own home, La Maison Sanofi, in Paris... Stay tuned! ✨
-
Whether in sports or in science, we’re as committed as the team of people who stand behind us. Ask #TeamSanofi member Ezra Frech and Youxin Kong, a Sanofi senior scientist and volunteer for the Olympic Games #Paris2024. 🥇 #WeNeverSettle #IgnitingPotential #Olympics #Paralympics Paris 2024 - Comité d'organisation des Jeux Olympiques et Paralympiques de 2024
-
How can #AI help improve diversity within clinical operations without bias? 🤝 We know that fairness, diversity, and equity in AI development is key to a future where #healthcare is truly inclusive and accessible to all. Lionel Bascles, our Head of Clinical Sciences & Operations, explains how our teams are working towards this goal. ⬇️ Learn more about our Responsible AI approach: http://spkl.io/604247nDw
-
We have been named No. 7 and 1 in the Pharma Industry on TIME's list of the World's 500 Most Sustainable Companies! Our work on environmental sustainability and resilience matters deeply to us. We work hard at being good to our planet, and our dedication to improving people’s lives goes beyond innovations in healthcare. Learn how we’re minimizing the environmental impacts of our products and activities ➡️ http://spkl.io/604147b5d #Sustainability
-
The European Commission has approved our treatment for adults with uncontrolled chronic obstructive pulmonary disease (#COPD). This first-ever targeted therapy for adults with COPD is also the first new treatment approach for the disease in more than a decade. Read more about the news: https://lnkd.in/epA-WbdW CC: Regeneron
-
Our Team Sanofi athletes and Sanofians have a message for you! 👀 There are just 24 days to go until the Olympic and Paralympic Games #Paris2024! All Sanofians will be cheering on our amazing #TeamSanofi! Together, we never settle. 🫶 #IgnitingPotential #WeNeverSettle Paris 2024 - Comité d'organisation des Jeux Olympiques et Paralympiques de 2024
-
Our commitment to AI is integrated across our entire drug development process. One of the most exciting examples is the development and leveraging of virtual patient populations, more commonly (and fondly) known as “digital twins.” Sanofi’s Global Head of Translational Disease Modeling Thomas Klabunde explains how digital “twinning” works and how it is helping accelerate the R&D process across asthma and other immune-mediated diseases. Read more: http://spkl.io/6040471ZA
-
Ever wonder what it's like to be an official #Torchbearer for the Paris 2024 Olympic Torch Relay? We captured some of the most exclusive and exciting moments from behind the scenes with #Paris2024, when the #Olympic Flame Paris 2024 stopped by our site in Neuville-sur-Saône, France 🙌
-
The New England Journal of Medicine (NEJM Group) has published positive Phase 3 results regarding our medicine in children aged 1 to 11 years with eosinophilic esophagitis (#EoE). Read more about how we are working with Regeneron to change the standard of care for young children living with the disease. Read our press release: http://spkl.io/604447BBQ
Pages affiliées
Pages similaires
Parcourir les offres d’emploi
Financement
Dernier round
Capital après introduction en Bourse329 024 935,00 $US
Investisseurs
Blackstone Life Sciences